You just read:

Janssen Submits Application To EMA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis

News provided by

Janssen-Cilag International NV

25 Nov, 2016, 12:30 GMT